← Back to Search
Cognitive Response To Pharmacological Treatment For Depression In Alzheimer Disease: Secondary Outcomes From The Depression In Alzheimer's Disease Study (DIADS).
C. Munro, J. Brandt, J. Sheppard, C. Steele, Q. Samus, M. Steinberg, P. Rabins, C. Lyketsos
Published 2004 · Psychology, Medicine
Save to my Library
Download via 🐼 PaperPanda Download via oaDOI Download via OAB Download via LibKey Download via Google Google ScholarAnalyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
OBJECTIVE The authors assessed the cognitive effects of depression treatment with sertraline in patients with Alzheimer disease (AD) and major depression. METHODS Forty-four patients with probable AD and major depression were enrolled in a double-blind, placebo-controlled clinical trial of sertraline. Cognitive testing was done at baseline and at 3-week intervals throughout the 12-week study. At the 12th week, subjects were categorized by treatment response (full, partial, or no response). Cognitive data from 41 participants who completed three or more testing sessions and 36 who completed all five study visits were included in the analyses. RESULTS Neither improved mood nor use of sertraline was associated with cognitive change over time in AD patients. Post-hoc exploration of the data, however, suggested a sex difference in cognitive response to sertraline such that women treated with sertraline demonstrated improved cognition compared with women on placebo, whereas men treated with sertraline worsened significantly in cognition compared with men on placebo. CONCLUSIONS In this study, among depressed AD patients after treatment with sertraline or placebo, there was no evidence that improved mood was associated with cognitive improvement. Future studies aimed at increasing power to detect mood as well as medication effects will be valuable in determining the relationship between cognition and treatment of depression in AD patients.
This paper references
A RATING SCALE FOR DEPRESSION
M. Hamilton (1960)
"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.
M. Folstein (1975)
Random-effects models for longitudinal data.
N. Laird (1982)
Cornell scale for depression in dementia
G. Alexopoulos (1988)
Acute effects of sertraline, amitriptyline, and placebo on the psychomotor performance of healthy subjects over 50 years of age.
M. Mattila (1988)
Subcortical hyperintensity on magnetic resonance imaging: a comparison of normal and depressed elderly subjects.
C. E. Coffey (1990)
Psychiatric phenomena in Alzheimer's disease. III: Disorders of mood.
A. Burns (1990)
Affinity modulation of [3H]imipramine, [3H]paroxetine and [3H]citalopram binding to the 5-HT transporter from brain and platelets.
P. Plenge (1991)
White matter hyperintensity signals in psychiatric and nonpsychiatric subjects.
F. W. Brown (1992)
Subcortical hyperintensities on magnetic resonance imaging: Clinical correlates and prognostic significance in patients with severe depression
I. Hickie (1995)
Comparative behavioural toxicity of the selective serotonin reuptake inhibitors
N. Sherwood (1995)
The prevalence, associations and symptoms of depression amongst dementia sufferers.
C. Ballard (1996)
P-1-8 Sertraline and nortriptyline: Heart rate, cognitive improvement and quality of life in depressed elderly
W. Mcentee (1996)
A quantitative review of cognitive deficits in depression and Alzheimer-type dementia.
H. Christensen (1997)
Cognitive impairment in the euthymic phase of chronic unipolar depression.
S. Paradiso (1997)
Major and minor depression in Alzheimer's disease: prevalence and impact.
C. Lyketsos (1997)
Is subcortical disease associated with a poor response to antidepressants? Neurological, neuropsychological and neuroradiological findings in late-life depression.
S. Simpson (1998)
Neuropsychological correlates of apathy and depression in patients with dementia
G. Kuzis (1999)
Depression does not aggravate the episodic memory deficits associated with Alzheimer's disease.
K. Fahlander (1999)
A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients.
P. Newhouse (2000)
Mental and Behavioral Disturbances in Dementia: Findings from the Cache County Study on Memory in Aging
C. Lyketsos (2000)
Changes in cognitive functioning following treatment of late-life depression.
M. Butters (2000)
Sex differences in extrastriatal dopamine d(2)-like receptors in the human brain.
V. Kaasinen (2001)
Negligible Effects of Depression on Verbal and Spatial Performance in Alzheimer’s Disease
A. Berger (2001)
Sex differences in [123I]β‐CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers
J. Staley (2001)
Cognitive and psychomotor effects of paroxetine and sertraline on healthy elderly volunteers.
P. Furlan (2001)
Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background.
J. Olin (2002)
Hippocampal volume and antidepressant response in geriatric depression
M. Hsieh (2002)
Stress and depression: possible links to neuron death in the hippocampus.
A. L. Lee (2002)
The relationship of MRI subcortical hyperintensities to treatment response in a trial of sertraline in geriatric depressed outpatients.
S. Salloway (2002)
Executive dysfunction in geriatric depression.
K. Lockwood (2002)
Longitudinal increase in the volume of white matter hyperintensities in late‐onset depression
R. Nebes (2002)
Cognitive deficits in major depression.
B. Ravnkilde (2002)
Brain morphometric abnormalities in geriatric depression: long-term neurobiological effects of illness duration.
Sandra Bell-McGinty (2002)
Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS.
C. Lyketsos (2003)
Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study
M. Steinberg (2004)
Psychopharmacological effects of sertraline in normal, healthy volunteers
I. Hindmarch (2004)
A randomized, placebo‐controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil
S. Finkel (2004)
On central effects of serotonin re-uptake inhibitors: Quantitative EEG and psychometric studies with sertraline and zimelidine
B. Saletu (2005)
This paper is referenced by
The tricyclic antidepressant clomipramine inhibits neuronal autophagic flux
F. Cavaliere (2019)
Effects of Psychotropic Medication on Cognition, Caregiver Burden, and Neuropsychiatric Symptoms in Alzheimer's Disease over 12 Months: Results from a Prospective Registry of Dementia in Austria (PRODEM).
A. Pirker-Kees (2019)
Cognitive dimensions of depression: Assessment, neurobiology, and treatment
S. Jeon (2018)
A meta-analysis of the effects of antidepressants on cognitive functioning in depressed and non-depressed samples
C. E. Prado (2018)
Impact of Antidepressant Use on the Trajectory of Alzheimer’s Disease: Evidence, Mechanisms, and Therapeutic Implications
R. Khoury (2018)
What is the therapeutic value of antidepressants in dementia? A narrative review
N. Farina (2017)
Depression in Alzheimer's Disease
Y. T. Kwak (2014)
Guidelines for the treatment of patients with dementia
A. Kogoj (2014)
Effect of Medications on Physical Function and Cognition in Nursing Home Residents with Dementia
Sarah K. Dutcher (2014)
KAKOVOST IN VARNOST/QUALITY AND SAFETY
Blanka Kores (2014)
Depression in Alzheimer's disease: epidemiology, mechanisms, and management.
Song Chi (2014)
Effect of Selective Serotonin Reuptake Inhibitors in Alzheimer’s Disease with Comorbid Depression
Amir Ali Sepehry (2012)
The serotonergic system in ageing and Alzheimer's disease
Jose Julio Rodriguez (2012)
Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease.
C. Munro (2012)
Altered serotonergic neurotransmission as a main player in the pathophysiology of Alzheimer's disease : structural and ultrastructural studies in a triple transgenic mouse model of the disease
H. Noristani (2012)
Psychopharmacological Neuroprotection in Neurodegenerative Diseases, Part III: Criteria-Based Assessment: A Report of the ANPA Committee on Research
E. Lauterbach (2011)
Psychopharmacological neuroprotection in neurodegenerative diseases, part III: criteria-based assessment: a report of the ANPA committee on research.
E. Lauterbach (2011)
Long-Term Management of Dementia
D. Scharre (2011)
Psychopharmacological neuroprotection in neurodegenerative disease: heuristic clinical applications.
E. Lauterbach (2010)
Depression in Alzheimer's disease. Pathophysiology, diagnosis, and treatment.
P. Modrego (2010)
Psychopharmacological Neuroprotection in Neurodegenerative Disease: Heuristic Clinical Applications
E. Lauterbach (2010)
Preventing Alzheimer's disease and cognitive decline.
John W. Williams (2010)
Utilisation des antidépresseurs chez les sujets âgés déments : données actuelles
C. Belicard-Pernot (2009)
Pharmacological treatment of Alzheimer's dementia: State of the art and current dilemmas
M. Omerovic (2008)
Is Antidepressant Treatment Associated with Reduced Cognitive Decline in Alzheimer’s Disease?
E. Mossello (2008)
Safety and efficacy of psychopharmacological agents used to treat the psychiatric sequelae of common neurological disorders
C. Bernardo (2008)
Neurocognitive Costs and Benefits of Psychotropic Medications in Older Adults
J. Brooks (2007)
Management of mild to moderate Alzheimer’s disease and dementia
D. Hogan (2007)
Greater Impairment of Ability in the Divided Attention Task Is Seen in Alzheimer’s Disease Patients with Depression than in Those without Depression
S. Nakaaki (2007)
Depression and Cognitive Impairment in Older Adults
G. Potter (2007)
Diagnosis and treatment of depression in Alzheimer's disease: impact on mood and cognition.
B. Appleby (2007)
An open‐label study of escitalopram (Lexapro®) for the treatment of ‘Depression of Alzheimer's disease’ (dAD)
V. Rao (2006)See more